What is administered IV push following patient decompensation during the withdrawal process?

The administration of 300 units/kg of Heparin IV push following patient decompensation during the withdrawal process is grounded in its role in preventing thromboembolism, especially in patients who may experience changes in their hemostatic balance during withdrawal. During this critical phase, the patient may be at increased risk for clot formation due to altered blood viscosity and flow dynamics, particularly if there has been prolonged immobilization or other complications associated with withdrawal from substances.

Heparin, as an anticoagulant, will help mitigate this risk by inhibiting the formation of clots and facilitating better blood circulation. The specific dosing of 300 units/kg is aligned with established clinical protocols that have been shown to be effective in managing such scenarios, ensuring both safety and efficacy in the treatment of patients undergoing withdrawal and potentially facing decompensation.

This choice highlights the importance of tailored medical intervention during sensitive periods like withdrawal, focusing on maintaining homeostasis and reducing the risk of serious complications. The other options, while also involving Heparin, do not match the recommended dosing in this specific context and may either be inadequate or excessive, potentially leading to complications.